Recent Advances in Intravesical Chemotherapy: Insights into the FDA-Approved Gemcitabine-Releasing TAR-200 System for Bladder Cancer Management
{{output}}
The FDA approval of the gemcitabine intravesical system (Inlexzo/TAR-200) marks a breakthrough for BCG-unresponsive NMIBC with CIS. This novel drug-device combination enables sustained intravesical chemotherapy, achieving high complete response rates with acce... ...
